Clinical and molecular characterization of the cisplatin-vinorelbine chemotherapeutic regimen in HER2(-) metastatic breast cancer
Ontology highlight
ABSTRACT: Despite rapid advances in treatment options, challenges still persist in advanced breast cancer. Bevacizumab is a VEGF-neutralizing antibody with proven efficacy in combination with chemotherapy for treatment of HER2 negative metastatic breast cancer (mBC). Vinorelbine, a semisynthetic vinca alkaloid, is a well-established and well tolerated chemotherapeutic in breast cancer. The combination of vinorelbine with platinum and addition of bevacizumab is relatively underreported in the literature. We propose this combination regimen as safe, well tolerated and efficacious in HER2 negative mBC patients.
ORGANISM(S): Homo sapiens
PROVIDER: GSE267621 | GEO | 2024/05/16
REPOSITORIES: GEO
ACCESS DATA